Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 12, 2022

Updated Efficacy and Safety of Pembrolizumab in Patients With Advanced HCC Previously Treated With Sorafenib

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Eur. J. Cancer 2022 May 01;167(xx)1-12, M Kudo, RS Finn, J Edeline, S Cattan, S Ogasawara, DH Palmer, C Verslype, V Zagonel, L Fartoux, A Vogel, D Sarker, G Verset, SL Chan, J Knox, B Daniele, T Yau, EB Gurary, AB Siegel, A Wang, AL Cheng, AX Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading